

# Niacinamide




## Ingredient Research Highlights



### Topical niacinamide significantly improved hyperpigmentation.

In a double-blind, randomized clinical trial of 27 melasma patients, topical 4% niacinamide applied for 8 weeks significantly reduced pigmentation, with a 62% reduction in MASI score from baseline.



### Niacinamide demonstrated comparable pigment improvement to hydroquinone.

Patients applied 4% niacinamide to one side of the face and 4% hydroquinone to the other. Objective colorimetric measurements showed no statistically significant difference between the two treatments, indicating niacinamide provided similar visible pigment improvement.



### Inflammation and mast cell infiltrate were significantly reduced.

Histological analysis of skin biopsies showed mast cell counts decreased from 22 to 16 cells/mm<sup>2</sup>, indicating anti-inflammatory activity in melasma-affected skin.



### Epidermal melanin levels were significantly reduced.

Digital image analysis of biopsy samples demonstrated a significant reduction in epidermal melanin deposition after treatment with niacinamide, supporting its role in improving uneven pigmentation.



### Niacinamide demonstrated a favorable safety profile.

Side effects occurred in 18% of niacinamide-treated patients compared to 29% with hydroquinone, and reactions were generally milder, suggesting niacinamide may be a well-tolerated alternative for long-term treatment.

## How This Translates to Our Formula

- Helps visibly improve uneven skin tone and hyperpigmentation
- Supports reduction of excess melanin deposition in the skin
- Provides anti-inflammatory support for irritated or sensitive skin
- Helps improve overall skin clarity and brightness
- Designed to promote a more even-looking complexion with excellent tolerability



Source: Navarrete-Solis J, Castanedo-Cázares JP, Torres-Álvarez B, et al.

A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. *Dermatology Research and Practice*. 2011;2011:379173.doi:10.1155/2011/379173.